Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?
1. BMY expects Q2 2025 earnings of $1.585 per share. 2. Slight downward revenue revisions anticipated for 2025. 3. Discussion on U.S. drug pricing policies will be crucial. 4. Analyst rating remains Neutral with a price forecast of $56. 5. BMY faces significant medium-term growth challenges from generic competition.